All Stories

  1. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

    Article • OncoImmunology, June 2019, Taylor & Francis

    MD, Ph.D Jeong JH Heo, Caroline Breitbach, Philippe MERLE

  2. Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques

    Article • June 2015, Elsevier

    Caroline Breitbach, Dr Sergio A Acuna

  3. Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

    Article • March 2015, Elsevier

    Caroline Breitbach

  4. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

    Article • Oncolytic Virotherapy, January 2015, Taylor & Francis

    Caroline Breitbach, Mathieu Crupi

  5. First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

    Article • January 2015, Elsevier

    Caroline Breitbach

  6. Going viral with cancer immunotherapy

    Article • Nature Reviews Cancer, July 2014, Springer Science + Business Media

    Caroline Breitbach

  7. Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1

    Article • Frontiers in Oncology, May 2014, Frontiers

    Caroline Breitbach

  8. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

    Article • Nature Reports Stem Cells, February 2013, Springer Science + Business Media

    Caroline Breitbach

  9. Achieving efficient systemic delivery of oncolytic Vaccinia virus

    Article • Immunobiology, November 2012, Elsevier

    Caroline Breitbach

  10. Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594

    Article • Current Pharmaceutical Biotechnology, June 2012, Bentham Science Publishers

    Caroline Breitbach

  11. The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

    Article • April 2012, Elsevier

    Caroline Breitbach

  12. A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma

    Article • October 2011, Elsevier

    Caroline Breitbach

  13. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

    Article • Nature, August 2011, Springer Science + Business Media

    Caroline Breitbach

  14. Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

    Article • June 2011, Elsevier

    Caroline Breitbach

  15. Targeting Tumor Vasculature With an Oncolytic Virus

    Article • May 2011, Elsevier

    Caroline Breitbach

  16. Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors

    Article • PLoS ONE, December 2010, PLOS

    Caroline Breitbach

  17. Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma

    Article • November 2010, Elsevier

    Caroline Breitbach

  18. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: No shortcuts on the road to approval

    Article • Cytokine & Growth Factor Reviews, April 2010, Elsevier

    Caroline Breitbach

  19. Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses

    Article • Cytokine & Growth Factor Reviews, April 2010, Elsevier

    Caroline Breitbach

  20. Translational control of the innate immune response through IRF-7

    Article • Nature, February 2008, Springer Science + Business Media

    Caroline Breitbach

  21. Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow

    Article • September 2007, Elsevier

    Caroline Breitbach

  22. Structures of aminoglycoside acetyltransferase AAC(6′)-Ii in a novel crystal form: structural and normal-mode analyses

    Article • Acta Crystallographica Section D Biological Crystallography, August 2005, International Union of Crystallography

    Caroline Breitbach